Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Astria Therapeutics Inc ATXS

Healthcare Biotechnology
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a... see more

Recent & Breaking News (NDAQ:ATXS)

Catabasis Pharmaceuticals Reports First Quarter 2018 Financial Results and Reviews Business Progress

Business Wire May 10, 2018

Catabasis Pharmaceuticals to Report First Quarter 2018 Financial Results and Recent Corporate Developments on Thursday, May 10

Business Wire May 3, 2018

Benzinga Pro's 5 Stocks To Watch Today

Benzinga.com  April 26, 2018

Catabasis Pharmaceuticals Presents New Edasalonexent Data Showing Significantly Slowed Duchenne Muscular Dystrophy Disease Progression as Measured by MRI Through One Year of Treatment

Business Wire April 25, 2018

Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent in Duchenne Muscular Dystrophy at the American Academy of Neurology 70th Annual Meeting

Business Wire April 18, 2018

Catabasis Pharmaceuticals Aligns Resources to Focus on Lead Program Edasalonexent for the Treatment of Duchenne Muscular Dystrophy

Business Wire April 17, 2018

Catabasis Pharmaceuticals Reports Positive Results from Open-Label Extension of Phase 2 MoveDMD® Trial Evaluating Edasalonexent in Duchenne Muscular Dystrophy and Plans to Initiate Phase 3 Clinical Trial in First Half 2018

Business Wire October 4, 2017

Catabasis Pharmaceuticals to Present Results from Joint Research Collaboration with Sarepta Therapeutics at the 22nd International Congress of the World Muscle Society

Business Wire September 28, 2017

Catabasis Pharmaceuticals to Present Results from the Open-Label Extension of the MoveDMD® Phase 2 Trial of Edasalonexent in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society

Business Wire September 14, 2017

Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call

Accesswire August 10, 2017

Catabasis Pharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference

Business Wire August 9, 2017

Catabasis Pharmaceuticals to Report Second Quarter 2017 Financial Results and Recent Corporate Developments on Thursday, August 10

Business Wire July 27, 2017

Catella AB (publ) Publishes Bond Prospectus and Applies for Listing of its Bonds on Nasdaq Stockholm

PR Newswire Europe Non Regulatory July 27, 2017

Catella Establishes Operations in the Netherlands

PR Newswire Europe Non Regulatory July 11, 2017

Catabasis Pharmaceuticals to Present Results from the MoveDMD® Trial of Edasalonexent (CAT-1004) at the 2017 PPMD Annual Connect Conference

Business Wire June 23, 2017

Pre-Market Technical Recap on Biotech Stocks -- Array BioPharma, Catabasis Pharma, Cerulean Pharma, and Immunomedics

PR Newswire June 21, 2017

Catella AB (publ) Calls for Early Redemption of its Outstanding SEK 200 Million Bond Loan 2012/2017

PR Newswire Europe Non Regulatory June 15, 2017

Catabasis Pharmaceuticals Presents New Data for CAT-5571 as a Novel Potential Oral Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference

Business Wire June 8, 2017

Catabasis Pharmaceuticals to Present CAT-5571, a Novel Activator of Autophagy, as a Potential Treatment for Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference

Business Wire June 2, 2017

Catabasis Pharmaceuticals Reports First Quarter 2017 Financial Results and Reviews Business Progress

Business Wire May 11, 2017